There Is No Interaction Between BMI and SGLT2 Inhibitor Efficacy in HF, Review Finds
Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.
Source: ajmc.com
